20 September 2025
: Case report 
Pediatric Liver Transplant Complications: EBV-Associated Tumors and Infection Management Strategies
Rare coexistence of disease or pathology
Li-Na Wu ABCDEF 1,2,3,4, Zhi-Gui Zeng BDE 2,3,4,5, Jing-Yi Liu
CDE 1,6,3,4, Lin Wei BD 6,3,4,5, Yu-Le Tan B 6,3,4,5, Fu-Xiao Xie CD 6,3,4,5, Zhi-Jun Zhu AF 6,3,4,5*, Li-Ying Sun A 1,6,3,7
DOI: 10.12659/AJCR.948566
Am J Case Rep 2025; 26:e948566
Table 1 Treatment response timeline in our case.
| Time after LT (mo) | Intervention | Liver lesion (cm) | Spleen lesion (cm) | EBV DNA (copies/ml) |
|---|---|---|---|---|
| 30.9 | RIS and Rituximab initiation | 0.9×0.6 | Not detected | 3×10 |
| 38.6 | Sirolimus initiation | 1.3×1.3 | 4.0×3.2 | 1×10 |
| 47.4 | Splenectomy | Resected | Resected | Undetectable |
| The latest | Sirolimus | Not detected | Not detected | 700 |